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In  2005,  a year  after  highly  pathogenic  avian  inﬂuenza  outbreaks  in  Thailand,  the  Thai Government
issued  a  National  Strategy  Plan  for Pandemic  Inﬂuenza  Preparedness,  a major  objective  of which  was  the
domestic  production  of seasonal  inﬂuenza  vaccine.  It was  considered  that  sustained  inﬂuenza  vaccine
production  was  the  best  guarantee  of  a pandemic  vaccine  in  the  event  of  a future  pandemic.  The  Govern-
ment  decided  to provide  funds  to  establish  an  industrial-scale  inﬂuenza  vaccine  production  plant,  and
gave  responsibility  for  this  challenging  project  to the  Government  Pharmaceutical  Organization  (GPO).
In  2007,  with  support  from  the  World  Health  Organization  (WHO),  the GPO  started  to  develop  egg-based,
trivalent  inactivated  inﬂuenza  vaccine  (IIV)  in  a  renovated  pilot plant.  In  early  2009,  during  the  second
year  of  the  project,  the GPO  turned  its attention  to  develop  a pandemic  live  attenuated  inﬂuenza  vac-
cine  (PLAIV)  against  the  inﬂuenza  A (H1N1)  virus.  By December  2010,  the  H1N1  PLAIV  had  successfully
completed  Phase  II clinical  trials  and  was  awaiting  registration  approval  from  the  Thai  Food  and  Drug
Administration  (TFDA).  The  GPO  has  also  started  to develop  an H5N2  PLAIV,  which  is  expected  to enter
clinical  trials  in  January  2011.  The  next  step  in  2011  will  be  the  development  and  clinical evaluation
of  seasonal  LAIV.  To  meet  the  needs  of  the  national  seasonal  inﬂuenza  vaccination  programme,  the  GPO
aims  to produce  2 million  doses  of  trivalent  IIV in  2012  and  progressively  increase  production  to  the  max-
imum  annual  capacity  of 10 million  doses.  This article  relates  how  inﬂuenza  vaccine  production  capacity
was  developed  and  how  major  challenges  are  being  met  in an  expeditious  manner,  with  strong  local  and
global  commitment.. Introduction
In 2004, avian inﬂuenza outbreaks caused high case-fatality
ates – 17 of the 25 reported H5N1-infected patients in Thailand
ied. This highlighted the urgency for Thailand to secure sus-
ainable access to pandemic vaccine. Indeed, the current global
andemic inﬂuenza vaccine production capacity would be grossly
nadequate if the world’s population needed to be immunized [1].
he threat of highly pathogenic avian inﬂuenza viruses is partic-
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ularly acute in developing countries, as it is unlikely that they
would have access to pandemic vaccine, and their health services
would be inadequate to deal with such an emergency [2]. The Min-
istry of Public Health, Thailand thus included the establishment of
domestic inﬂuenza vaccine production as a key element of its ﬁrst
ﬁve-year National Strategy Plan for Pandemic Inﬂuenza Prepared-
ness in 2005. In order to sustain future production capacity, the
National Health Security Board approved free seasonal inﬂuenza
vaccine for the elderly and individuals suffering from chronic dis-
eases. As a result of this initiative, coverage rates for these high-risk
Open access under CC BY-NC-ND license.groups increased from 400,000 in 2007 to 2 million in 2009, and
should reach 4 million people by 2011.
The Thai Government allocated US$ 42 million towards the
establishment of an industrial-scale inﬂuenza vaccine production
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lant at Kaeng-Koi, Saraburi province, under the responsibility
f the Government Pharmaceutical Organization (GPO). With the
ommitment of the Government and the World Health Organi-
ation (WHO), the GPO became one of the ﬁrst six grantees of
he WHO  initiative to support developing countries to produce
andemic inﬂuenza vaccine. The original scope of the grant was
o develop egg-based subunit inactivated inﬂuenza vaccine (IIV)
or seasonal use. Since the H1N1 pandemic in 2009, the grant
as also included the development of pandemic live attenuated
nﬂuenza vaccine (PLAIV). As the GPO had no previous experience
ith inﬂuenza vaccine, an external expert was recruited to help
stablishing the technology on site.
. Development of inactivated inﬂuenza vaccine
The GPO started to renovate a BSL2 laboratory at the Faculty of
harmacy, Silpakorn University in Nakorn Pathom province for the
aboratory-scale production of IIV. In 2009, this laboratory was fur-
her renovated into a BSL3 pilot plant for the production of LAIV
or clinical trials, and for the production of PLAIV in the case of a
andemic. Following inspection by WHO  experts and the Thai Food
nd Drug Administration (TFDA) in July 2009, the plant was certi-
ed compliant with current Good Manufacturing Practices (cGMP)
or the production of clinical lots, and for the production of vaccines
or wider use in the case of a pandemic.
During 2007–2008, the GPO staff acquired the skills and tech-
iques to carry out laboratory-scale studies in the new facilities
nder guidance from an external expert supported by WHO, at spe-
ialized courses at the National Institute for Biological Standards
nd Control (NIBSC) in the United Kingdom and at the Netherlands
accine Institute (NVI). The training included potency tests (single
adial immunodiffusion (SRID), electrophoresis, egg management
nd handling, inoculation and harvesting, clariﬁcation, puriﬁcation
nd concentration for puriﬁed whole virus concentrate and inac-
ivation to obtain ﬁnal bulk of monovalent sub-unit vaccine for
/H1N1, A/H3N2 and B strains.
The Sahafarm poultry farm in Thailand provided vaccine-quality
rown-shell clean embryonated 10–11 day old eggs. The param-
ters of each step of the inoculation of the eggs and harvest
f allantoic ﬂuid were optimized to obtain the highest yield.
n addition to building capacity for the production process, the
PO staff developed skills to perform assays for quality con-
rol, such as the haemagglutination, SRID and residual infectivity
ests, as well as for quantitative determination of protein, oval-
umin, formaldehyde, sucrose, and triton X-100 concentration.
ithin one year, the GPO developed laboratory-scale produc-
ion of seasonal IIV with a yield of more than 1 dose per egg (1
ose of each strain contains at least 15 g/0.5 ml). Data obtained
uring the laboratory-scale development of IIV are shown in
able 1.
Meanwhile, the project to establish a US$ 42 million industrial-
cale plant for IIV was approved by the Cabinet in 2007. Following
he design, budgeting and bidding processes, construction of the
lant commenced in 2009. In parallel, the National Health Secu-
ity Board approved the provision of free seasonal IIV to high-risk
roups, including the elderly and persons with one of seven chronic
iseases. This will create a regular domestic market of around
 million doses for seasonal IIV, sufﬁcient to maintain future
ndustrial-scale production and serve as a reserve for future pan-
emic response.
The  rapid spread in 2009 of A (H1N1) inﬂuenza across all con-
inents compelled the GPO to move its focus away from IIV to
he development of a pandemic A (H1N1) LAIV. Indeed, the much
uperior yields obtained with LAIV compared to IIV make this tech-
ology a promising approach to increase production capacity in the
ase of a pandemic.9S (2011) A29– A33
3. Development of an H1N1 live attenuated inﬂuenza
vaccine
A  sub-licence signed in April 2009 with WHO  to obtain the
Russian LAIV coincided with the onset of an A (H1N1) inﬂuenza
outbreak. An emergency plan was  thus set up to produce a LAIV
from A/17/CA/2009/38 (H1N1), cold adapted/temperature sensi-
tive (ca/ts) reassortant pre-master seed produced from master
donor virus (MDV) A/Leningrad/134/17/57 (H2N2) and wild type
A/California/07/2009 (H1N1). Development of the monovalent egg-
based PLAIV started in July 2009.
Genetic stability of the candidate vaccine after four passages
was carried out by the GPO in collaboration with the Faculty of Sci-
ence, Mahidol University, Thailand. Complete nucleotide sequence
of the pre-master, master and working virus seeds, as well as of
clinical lots were determined. Sequences around known mutations
in the PB2 (V-478-L), PB1 (K-265-N, V-591-I) and PA (L-28-P, V-
341-L) genes in the vaccine strain were compared to those that
play a critical role in the attenuation of the ca Len/17 vaccine donor
strain [3]. Apart from a novel mutation in NS (T-191-K) found in all
virus preparations analysed, and which is not located in any of the
regions of the genome known to contribute to virus attenuation,
the genetic sequences were found to correspond exactly to those
expected, showing the stability of the vaccine virus.
The  need to import 5000 speciﬁc pathogen free (SPF) eggs per
week from Germany and the United States of America (USA) for
the production of LAIV initially posed problems for the handling,
management and ultimate quality of the eggs. It took some time
therefore to optimize the processes to obtain high virus yields and
volumes of harvested allantoic ﬂuid. To overcome a foreseeable
shortage of both SPF and clean eggs, the GPO has initiated dis-
cussions with egg suppliers in Thailand regarding investment in
a poultry farm to secure sufﬁcient quantities of quality eggs for
future production of both IIV and LAIV.
3.1. Non-clinical tests for safety and immunogenicity
A single dose toxicity study carried out at the GPO in out-
bred ICR female mice compared four vaccine dosage levels given
intraperitoneally: normal saline solution (group 1, control); 7.9 log
at 50% of the egg infectious dose (EID50) of the GPO PLAIV (group
2); the GPO placebo (group 3) and 7.3 log EID50 of FluMist LAIV
(group 4, comparative vaccine). One week of follow-up showed no
evidence of toxicity or infection attributable to the vaccine, and
all subjects gained weight and survived. A repeated dose toxicity
study compared the toxicity of 6.8 log EID50 of the GPO PLAIV given
intranasally to inbred BALB/c mice against the control group, the
GPO placebo and 6.6 log EID50 of the comparative vaccine at Day  0
and Day 7. After 21 days’ monitoring post ﬁrst inoculation, there
was no evidence of toxicity or infection attributable to the vaccine,
and all mice gained weight and survived (Fig. 1). Results of haema-
tology and serum chemistry showed no abnormal values related
to the LAIV. The necropsy results showed no lesions related to the
LAIV, nor did histopathology results in immune or pivotal organ
and administration site (nasal turbinate bone). The GPO vaccine
and placebo groups and the comparative vaccine showed slight
to mild interstitial pneumonia that may  relate to viral infection.
The difference in means of the lesion scores from the GPO vac-
cine and comparative vaccine groups was non-signiﬁcant when
analysed by independent samples t-test (p value ≤ 0.05). This study
demonstrated that the GPO PLAIV was indistinguishable from the
comparative vaccine, in terms of acute toxicity.The reassortant progeny, containing six internal genes from
ca MDV  and two  external genes for haemagglutinin (HA) and
neuraminidase (NA) from wild type virus, was  selected and
proved for identity, immunogenicity and toxicity in mice and
S. Surichan et al. / Vaccine 29S (2011) A29– A33 A31
Table 1
Laboratory-scale development of inactivated trivalent inﬂuenza vaccine.
H3N2 H1N1 B
Lot A Lot B Lot A Lot B Lot A Lot B
Monovalent bulk of inactivated sub-unit vaccine
Strain X-157 X-157 IVR-145 IVR-145 Malaysia Malaysia
No.  of clean eggs 400 590 370 407 300 300
Average  volume of harvested allantoic acid (ml) per egg 9.39 8.78 10.11 9.29 10.24 10.6
Titre  at harvesting step (HA) 1280 640 1280 1280 320 640
Sub-unit  vaccine
Volume  (ml) 490 450 180
HA  content (g/ml) (SRID assay) 216 209.4 120.05
Protein  content (g/ml) 178.17 208.56 106.58
Triton-x  content (g/ml) 5.17 5.06 0.5
Formaldehyde content (g/ml) 48.06 81.39 67.52
Ovalbumin content (ng/ml) 36.24 ND 6.05
Sucrose  content (%) 2.3  0 0
Inactivation test Pass Not pass Pass
No.  of doses/egg 3.59 4.04 1.20
HA, haemagglutinin; SRID, single radial immunodiffusion.
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Dig. 1. Mean weights of mice for 21 days post ﬁrst inoculation in repeated dose to
nd comparative vaccine = FluMist].
uinea pigs by the Institute of Experimental Medicine (IEM),
ussia and for immunogenicity and attenuation in ferrets by
iroClinics of the Erasmus Medical Centre, the Netherlands. The
esults showed that a single dose of PLAIV was sufﬁcient to
nduce adequate immune responses against the vaccine strain
irus (represented by A/California/EURRG4/2009). Moreover, vac-
inated animals proved to be protected against challenge with
 virulent wild type pandemic H1N1 virus (represented by
/Netherlands/EURRG602/2009) (Table 2)..2. Phase I clinical trial
A  double-blind randomized clinical study involving 24 par-
icipants aged 18–49 years was carried out to assess the safety
able 2
mmunogenicity of LAIV A/17/California/2009/38 (H1N1) in ferrets after single-dose imm
HAI assay Average HAI titre (6 ferrets)
HAI at Day 0 
Group/testing viruses A/California/EURRG4/2009
(reassortant vaccine)
Negative control <10 
GPO  clinical trial grade PLAIV <10 
ata from ViroClinics, the Netherlands. HAI, haemagglutination inhibition. study Note: There were 10 mice per group [control = normal saline solution (NSS)
and  tolerability of two doses of the candidate LAIV vaccine using
two inoculum sizes (5.0–6.5 log EID50 or 6.6–7.5 log EID50) given
intranasally 21 days apart. Immune responses were also assessed
on Days 1, 21, 42 and 60 after ﬁrst vaccination. Blood sam-
ples were collected and assayed for haemagglutination inhibition
and microneutralizing antibodies. One subject showed positive
seroconversion as assayed against the GPO vaccine strain anti-
gens. Nasal swabs were performed on Days 2, 3, 5, and 7
after immunization to assess viral shedding by reverse tran-
scription polymerase chain reaction (RT-PCR). Only two samples
collected on Day 2 were positive for viral ribonucleic acid
(RNA). No serious adverse event was reported and all adverse
reactions suspected to be related to treatment were mild to
moderate.
unization.
HAI at Day 20
A/California/EURRG4/2009
(reassortant vaccine)
A/Netherlands/EURRG02/2009
(reassortant wild type virus)
<10 <10
866 876
A32 S. Surichan et al. / Vaccine 2
Table  3
Immune responses after 1 and 2 doses in adult volunteers (>18–49 years old) vac-
cinated with PLAIV.
Positive by MN  after
1  dose
Positive by MN after
2  doses
Low-dose vaccine 1/6 17% 3/6 50%
High-dose vaccine 2/18 11% 11/18 61%
Placebo 0/8 0% 0/8 0%
MN,  microneutralization. Of 45 volunteers selected randomly from the Phase I and
II, 13 were seropositive at Day 1. Only data from the 32 volunteers seronegative
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ct  Day 1 were considered in the analysis. Low dose: 5.0–6.5 log EID50 High dose:
.6–7.5  log EID50 The MN tests were performed at NIBSC, United Kingdom.
.3. Phase II clinical trial
The  GPO H1N1 PLAIV entered Phase II clinical trials in May
010 to evaluate the safety and immunogenicity of the vaccine
n a larger group of 324 volunteers divided equally into three age
roups, i.e. 12–18, >18–49 and >49 years old. Two doses of vac-
ine at 6.6–7.5 log EID50 were administered 21 days apart. Immune
esponses after 1 and 2 doses in volunteers aged >18–49 year
ld vaccinated with PLAIV are shown in Table 3. Based on the
esults of this study, the GPO ﬁled a registration dossier with the
FDA in early December 2010 as the ﬁrst live inﬂuenza vaccine
roduced in Thailand. It will also ﬁle a registration dossier for
ll other age groups under study after completion of the clinical
rials.
The GPO PLAIV contains 7 log EID50 for nasal administration of
.25 ml/nostril. It is a liquid formulation kept frozen at −20 ◦C and
hawed just before use. While real time stability studies are in
rogress, the stabilizers used and recommended storage conditions
how the vaccine to be stable for at least 14 weeks at both −20 ◦C
nd 2–8 ◦C.
. Development of H5N2 live attenuated inﬂuenza vaccine
Following  the clinical study of H1N1 PLAIV and based on the
xperience acquired, the GPO decided to initiate the develop-
ent of an H5N2 LAIV to be used against H5N1 avian inﬂuenza,
hich is still a major threat in the region. This is in line with its
trategic goal of pandemic preparedness. Ca/ts virus pre-master
eed A/17/turkey/Turkey/05/133 (H5N2) was provided by IEM,
ussia and the ﬁrst lot of H5N2 LAIV concentrated bulk vac-
ine was produced with a high yield of 9 log EID50/0.5 ml.  The
accine is currently undergoing non-clinical testing as well as
esting for genotype and phenotype. Samples of the GPO H5N2
accine have been sent to the National Institute for public Health
nd the Environment (RIVM) for testing in ferrets, and Phase I
linical trials are planned to start in early 2011. Due to its expe-
ience with registration of the H1N1 LAIV, the GPO hopes to be
ble to register H5N2 as the second LAIV within a shorter time
rame.
. Development of seasonal live attenuated inﬂuenza
accine
In  case of future pandemics, it is likely that the GPO’s total
ndustrial-scale pandemic IIV capacity of 30 million doses would be
nadequate. Therefore, following completion of the development of
ts H5N2 LAIV, the GPO plans to develop and market a seasonal LAIV.
n this way, if and when a pandemic hits, the GPO will be able to
roduce both PLAIV and PIIV, the former for the general population
nd the PIIV for use in the general population as well as high-risk
roups, principally pregnant women, the elderly and persons with
hronic diseases. This will allow adequate supplies of pandemic9S (2011) A29– A33
vaccine  for the whole population, and even those of neighbouring
countries.
6. Seasonal inactivated inﬂuenza vaccine
The experience gained in the laboratory-scale production of
seasonal IIV and the development of pandemic H1N1 and H5N2
vaccines has prepared the GPO for the next stage of the inﬂuenza
vaccine project, i.e. to produce seasonal IIV at the pilot and indus-
trial scale. This is being facilitated by an agreement with the
Chemo-Sero Therapeutic Research Institute (Kaketsuken, Japan),
supported by the Japanese Government. The main purpose of
industrial-scale IIV production is for domestic use and to maintain
capacity for inﬂuenza pandemic preparedness.
Pending industrial-scale IIV production capacity in 2012, the
GPO plans to develop and produce seasonal LAIV for public use
(see Section 5 above). Once the new manufacturing plant is fully
operational, the GPO plans to produce 2 million doses of seasonal
egg-based trivalent IIV per year to meet local demand, and progres-
sively to increase production to the maximum annual capacity of
10 million doses. In addition, some pandemic IIV, such as H5N1,
will be developed and produced to create a vaccine stockpile for
pandemic use.
7.  Discussion
The primary objective of the inﬂuenza vaccine project in
Thailand is to ensure health security and economic stability at
the national, as well as the regional level. Building capacity for
self-reliance in a pandemic situation has thus been driven by pub-
lic health, and not commercial concerns. The strategy of Thailand
since 2007 has been to produce enough IIV to cover national sea-
sonal vaccine demand and to be able to convert this IIV production
capacity to manufacture monovalent vaccine in the event of a
pandemic. Indeed, the production plant designed to produce up
to 10 million doses of trivalent seasonal IIV should be able to
produce 30 million doses of monovalent IIV or up to 300–500
million doses of PLAIV per year. A combination of both would
be required during a pandemic, as pandemic IIV will be used for
high-risk groups. This is more than enough for Thailand, a coun-
try with 64 million people. Thus, Thailand’s capacity can also
contribute to meeting regional and global pandemic inﬂuenza
needs.
The GPO will continue to improve and sustain its capacity
through comprehensive collaborative programmes and mobi-
lize additional support for the industrial-scale plant. It will also
establish effective research and production management through
in-house and external training with partners.
The GPO started this project with no experience in inﬂuenza
vaccine production or technology partner. Within three years, it
has developed the capacity to produce laboratory-scale seasonal
IIV and pilot-scale PLAIV. This capacity includes staff knowl-
edge and skills, institutional capacity to manage the development
and production of inﬂuenza vaccine, and its extensive domes-
tic and international networks, particularly among all essential
laboratories within the country, notably at Mahidol Univer-
sity.
With the support of a bilateral partner to manufacture seasonal
IIV, and its key international partners, the GPO will soon be able to
produce both IIV and LAIV at industrial-scale. Strong policy support
from the Ministry of Public Health and the National Health Secu-
rity Ofﬁce for routine seasonal inﬂuenza vaccination in targeted risk
groups has also been critical. These collaborations, and the commit-
ment of the Thai Government, have enabled the GPO to serve as a
good example of equitable beneﬁt sharing of inﬂuenza viruses.
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There are, nevertheless, some serious challenges. First and fore-
ost is the management capacity of the GPO industrial plant as a
ovice in egg-based vaccine production. The second challenge is
he inexperience of the National Drug Regulatory Authority (TFDA)
n approving the LAIV, as the GPO LAIV is the ﬁrst to be registered in
hailand. The WHO  Technical Advisory Group, during its last visit to
he GPO facilities in December 2009, recommended the strengthen-
ng of regulatory capacity in Thailand to allow the timely processing
f pilot and industrial scale production, GMP  approval and ulti-
ately registration and market authorization, particularly for LAIV.
o address these ﬁrst challenges, new institutional structures and
oordination mechanisms are being put in place which should be
ully effective by 2012. In addition, a joint capacity-building pro-
ramme  formulated by the GPO, the TFDA, and the Department
f Medical Sciences, was approved by the GPO Board of Director
nd awaits budgeting approval by the Cabinet for capacity building.
he third challenge is ensuring public conﬁdence in the quality and
fﬁcacy of the inﬂuenza vaccines produced by GPO as a new manu-
acturer of these vaccines. The support from development partners,
specially WHO, contributes signiﬁcantly to achieving this goal. The
PO will prove its credibility by adhering to all the necessary steps
or quality control and assurance, and tests on all its vaccines. It will
lso build public conﬁdence by registering its vaccines with the Thai
DA and applying for WHO  prequaliﬁcation. The ﬁnal challenge is
he continuity of an effective supply of pre-master seeds for LAIV
roduction. It is hoped that the ongoing discussions will be success-
ul in establishing a sustainable and effective supply of pre-master
eeds, along with other necessary reagents, for manufacturers of
AIV.
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